First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.

2c ) .When we excluded the good prognosis subgroup (Q4 PFS) from the survival analysis, the SENS signature showed a trend in separating the PFS curves of “SENS+ without the 75 th percentile” (SENS+ w/o 75 th ) and SENS─ patients (mPFS values of 9.30 and 6.30 months, respectively; p = 0.560) (Fig. 2c ).

also in 53,322 other papers

Although the results did not reach statistical significance, they are in line with previous findings from the AtezoTribe study, in which patients bearing TMB-high tumors derived higher benefit from the addition of atezolizumab to FOLFOXIRI-bevacizumab 13 , 14 .

also in 111,027 other papers